M&A / Deals AZ forges ever-closer ties with China’s CSPC Pharma PharmaphorumAstraZeneca has returned to China's CSPC Pharma to fill its R D pipeline, reaching a new $1.77bn agreement to develop drugs for kidney diseases.Read full story pharminent July 2, 2026 (Last updated: July 3, 2026) Pharmaphorum AstraZeneca has returned to China’s CSPC Pharma to fill its R D pipeline, reaching a new $1.77bn agreement to develop drugs for kidney diseases. Read full story Post navigation Previous: Roche’s KRAS drug tops its rivals in lung cancer trialNext: Novartis receives European Commission approval for Itvisma for spinal muscular atrophy Related Stories M&A / Deals Boehringer signs AI drug discovery deal with Owkin pharminent September 3, 2026 M&A / Deals Novartis signs $3.2bn drug delivery deal with Alteogen pharminent September 3, 2026 M&A / Deals Ono Pharmaceutical joins forces with Aitia for drug discovery in neurology pharminent September 2, 2026